Tertiary amine N-oxides as bioreductive drugs: DACA N-oxide, nitracrine N-oxide and AQ4N - PubMed (original) (raw)
Tertiary amine N-oxides as bioreductive drugs: DACA N-oxide, nitracrine N-oxide and AQ4N
W R Wilson et al. Br J Cancer Suppl. 1996 Jul.
Abstract
Tertiary amine N-oxides of DNA intercalators with alkylamino sidechains are a new class of bioreductive drugs. N-oxidation masks the cationic charge of the amines, forming prodrugs with low DNA binding affinity and low toxicity which can be activated selectively by metabolic reduction under hypoxic conditions. This study compares three intercalator N-oxides (NC-NO, DACA-NO and AQ4N), which, respectively, give nitracrine (NC), DACA and AQ4 on reduction. In aerobic cell culture all three N-oxide were much less toxic than the corresponding amines, and showed large increases in cytotoxicity under hypoxia. The topoisomerase poisons DACA and AQ4 (and their N-oxides) were less active against non-cycling than cycling cells. However, only AQ4N was active against the mouse mammary tumour MDAH-MCa-4. This dialkylaminoanthraquinone-di-N-oxide has activity at least as great as the reference bioreductive drug RB 6145 against this tumour, both with and without radiation and when combined with the tumour blood flow inhibitor 5,6-dimethylxanthenone-4-acetic acid (DMXAA). It is suggested that the high in vivo activity of AQ4N relative to the other topoisomerase-targeted N-oxide, DACA-NO, may be in part due to release in hypoxic cells of an intracalator with sufficiently high DNA binding affinity that it is retained long enough to kill non-cycling cells when they eventually re-enter the cell cycle.
Similar articles
- Comparison of aromatic and tertiary amine N-oxides of acridine DNA intercalators as bioreductive drugs. Cytotoxicity, DNA binding, cellular uptake, and metabolism.
Siim BG, Hicks KO, Pullen SM, van Zijl PL, Denny WA, Wilson WR. Siim BG, et al. Biochem Pharmacol. 2000 Oct 1;60(7):969-78. doi: 10.1016/s0006-2952(00)00420-2. Biochem Pharmacol. 2000. PMID: 10974206 - Nitracrine N-oxides: effects of variations in the nature of the side chain N-oxide on hypoxia-selective cytotoxicity.
Lee HH, Wilson WR, Denny WA. Lee HH, et al. Anticancer Drug Des. 1999 Dec;14(6):487-97. Anticancer Drug Des. 1999. PMID: 10834270 - Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent.
Patterson LH. Patterson LH. Cancer Metastasis Rev. 1993 Jun;12(2):119-34. doi: 10.1007/BF00689805. Cancer Metastasis Rev. 1993. PMID: 8375016 Review. - Bioreductively activated antitumor N-oxides: the case of AQ4N, a unique approach to hypoxia-activated cancer chemotherapy.
Patterson LH. Patterson LH. Drug Metab Rev. 2002 Aug;34(3):581-92. doi: 10.1081/dmr-120005659. Drug Metab Rev. 2002. PMID: 12214668 Review.
Cited by
- Bioorthogonally activated reactive species for target identification.
Siriwongsup S, Schmoker AM, Ficarro SB, Marto JA, Kim J. Siriwongsup S, et al. Chem. 2024 Apr 11;10(4):1306-1315. doi: 10.1016/j.chempr.2024.03.002. Epub 2024 Apr 2. Chem. 2024. PMID: 38617077 - In vitro radiosensitization of breast cancer with hypoxia-activated prodrugs.
Aiyappa-Maudsley R, Elsalem L, Ibrahim AIM, Pors K, Martin SG. Aiyappa-Maudsley R, et al. J Cell Mol Med. 2022 Aug;26(16):4577-4590. doi: 10.1111/jcmm.17486. Epub 2022 Jul 16. J Cell Mol Med. 2022. PMID: 35841287 Free PMC article. - Targeting DNA topoisomerase IIα (TOP2A) in the hypoxic tumour microenvironment using unidirectional hypoxia-activated prodrugs (uHAPs).
Smith PJ, McKeown SR, Patterson LH. Smith PJ, et al. IUBMB Life. 2023 Jan;75(1):40-54. doi: 10.1002/iub.2619. Epub 2022 May 2. IUBMB Life. 2023. PMID: 35499745 Free PMC article. Review. - Hypoxia signaling: Challenges and opportunities for cancer therapy.
Ivan M, Fishel ML, Tudoran OM, Pollok KE, Wu X, Smith PJ. Ivan M, et al. Semin Cancer Biol. 2022 Oct;85:185-195. doi: 10.1016/j.semcancer.2021.10.002. Epub 2021 Oct 7. Semin Cancer Biol. 2022. PMID: 34628029 Free PMC article. Review. - Enamine _N_-Oxides: Synthesis and Application to Hypoxia-Responsive Prodrugs and Imaging Agents.
Kang D, Cheung ST, Wong-Rolle A, Kim J. Kang D, et al. ACS Cent Sci. 2021 Apr 28;7(4):631-640. doi: 10.1021/acscentsci.0c01586. Epub 2021 Mar 29. ACS Cent Sci. 2021. PMID: 34056093 Free PMC article.
References
- Mutat Res. 1983 Dec;112(6):329-44 - PubMed
- J Med Chem. 1986 Jun;29(6):879-87 - PubMed
- J Med Chem. 1987 Apr;30(4):664-9 - PubMed
- Eur J Cancer Clin Oncol. 1989 Feb;25(2):271-7 - PubMed
- Int J Radiat Oncol Biol Phys. 1992;22(4):693-6 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources